Abrégé

The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:1, preferably is VEGF222/NF and consists of SEQ ID NO:1.

Classes IPC  ?

• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and/or neuroprotection in a subject. Such VEGR-1 inhibitors include small organic molecules, peptides, antibodies, antibody fragments, antibody mimetics, or nucleic acids. Also, compositions, pharmaceutical compositions, medicaments and kits of parts that include VEGFR-1 inhibitors and their use for promoting myelination and/or neuroprotection in a subject.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/00 - Préparations médicinales contenant des peptides
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: —a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; —a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b); 15—a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

The present application relates to the storage of gases, using a porous composite based on a porous matrix and an organic compound confined in solid form within pores of the matrix with a diameter of less than 10 nm.

Classes IPC  ?

• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/32 - Imprégnation ou revêtement
• C01B 3/00 - HydrogèneMélanges gazeux contenant de l'hydrogèneSéparation de l'hydrogène à partir de mélanges en contenantPurification de l'hydrogène

Abrégé

The present invention concerns a material of formula (I): The present invention concerns a material of formula (I): wherein: A is Na or Li or a mixture of Na and Li, The present invention concerns a material of formula (I): wherein: A is Na or Li or a mixture of Na and Li, 1 < x < 3 , 0 ≤ y ≤ 1 , 0 ≤ z ≤ 1 M is an electro-active transition element or a mixture of at least two electro-active transition elements, M′ is a non electro-active element or a mixture of at least two non electro-active elements, and the material of formula (I) presents a V/Z ratio varying from 212 Å3 to 246 Å3.

Classes IPC  ?

• H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
• H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
• H01M 4/04 - Procédés de fabrication en général
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p. ex. au magnésium ou à l'aluminium

Abrégé

The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61K 40/13 - Lymphocytes B
• C07D 235/18 - BenzimidazolesBenzimidazoles hydrogénés avec des radicaux aryle liés directement en position 2
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 471/04 - Systèmes condensés en ortho
• C07K 14/54 - Interleukines [IL]
• C12N 5/0781 - Cellules BLeurs progéniteurs

Abrégé

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP/PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

A device for controlling and protecting a power transistor, comprising: a nominal switching circuit for the transistor, a short-circuit detection circuit which keeps the transistor in the conducting state and detects an increase or decrease in the voltage VGS of the transistor relative to reference voltages representative of a short-circuit of the transistor; a protection circuit which discharges the gate of the transistor after the detection of a short-circuit; and a circuit for measuring and controlling the nominal switching circuit, the short-circuit detection circuit and the protection circuit.

Classes IPC  ?

• H03K 17/0812 - Modifications pour protéger le circuit de commutation contre la surintensité ou la surtension sans réaction du circuit de sortie vers le circuit de commande par des dispositions prises dans le circuit de commande
• G01R 31/26 - Test de dispositifs individuels à semi-conducteurs
• H03K 17/18 - Modifications pour indiquer l'état d'un commutateur

Abrégé

The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl group as leaving group, which allows all side products to be separated from the radiolabelled product. Said compounds are therefore useful tools in a method for synthesizing iodo- or astatoarryl compounds, in particular radioiodo- or radioastatoaryl compounds. The present invention relates to a method for synthesizing iodo- or astatoaryl compounds comprising the reaction of an arylsulfonium compound with an iodide or astatide salt, respectively. The invention also relates to arylsulfonium compounds as such. The invention also concerns a method of synthesizing an iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoraryl compound.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 17/093 - Préparation d'hydrocarbures halogénés par remplacement par des halogènes
• C07C 45/63 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par introduction d'atomes d'halogènePréparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par substitution d'atomes d'halogène par des atomes d'autres halogènes
• C07C 201/12 - Préparation de composés nitrés par des réactions ne créant pas de groupes nitro
• C07C 247/06 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone acycliques d'un squelette carboné étant saturé et contenant des cycles
• C07C 253/30 - Préparation de nitriles d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes cyano
• C07C 381/12 - Composés sulfonium
• C07D 213/61 - Atomes d'halogènes ou radicaux nitro
• C07D 333/76 - Dibenzothiophènes
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Abrégé

A method for determining implementation parameters of an electronic circuit configured to process an input signal. The electronic circuit includes an analog portion having a plurality of parameterisable analog primitives and a digital portion having a plurality of parameterisable digital primitives. The digital portion is coupled to the analog portion by at least one analog-digital converter and/or at least one analog comparator with or without hysteresis. The method includes a phase of joint learning of the parameters of the plurality of parameterisable analog primitives and of the parameters of the plurality of parameterisable digital primitives.

Classes IPC  ?

• G06F 30/38 - Conception de circuits au niveau mixte des signaux analogiques et numériques
• G06F 30/337 - Optimisation de la conception
• G06F 30/373 - Optimisation de la conception
• G06N 3/084 - Rétropropagation, p. ex. suivant l’algorithme du gradient

Abrégé

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly (oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

Estimating the state of energy for a particular time, which includes: Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; estimating a maximum energy that can be delivered by the cell, assuming that the temperature and the current remain constant; and Estimating the state of energy for a particular time, which includes: receiving measurements of a temperature of the cell, of a voltage of the cell, and of a current exchanged by the cell; estimating an internal resistance of the cell; estimating an open circuit voltage of the cell; estimating a total energy delivered by the cell until the particular time; estimating a maximum energy that can be delivered by the cell, assuming that the temperature and the current remain constant; and subtracting the estimated total delivered energy from the estimated maximum energy.

Classes IPC  ?

• G01R 31/374 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p. ex. de la capacité ou de l’état de charge avec des moyens pour corriger la mesure en fonction de la température ou du vieillissement
• G01R 31/367 - Logiciels à cet effet, p. ex. pour le test des batteries en utilisant une modélisation ou des tables de correspondance
• G01R 31/3842 - Dispositions pour la surveillance de variables des batteries ou des accumulateurs, p. ex. état de charge combinant des mesures de tension et de courant
• G01R 31/389 - Mesure de l’impédance interne, de la conductance interne ou des variables similaires
• G01R 31/396 - Acquisition ou traitement de données pour le test ou la surveillance d’éléments particuliers ou de groupes particuliers d’éléments dans une batterie
• H01M 10/48 - Accumulateurs combinés à des dispositions pour mesurer, tester ou indiquer l'état des éléments, p. ex. le niveau ou la densité de l'électrolyte

Abrégé

The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

T-cell acute lymphoblastic leukemias (T-ALL) are aggressive hematological malignancies associated with poor clinical outcome. TP53 alterations (TP53Alt) were rarely identified in T-ALL at diagnosis and their prognostic impact remains unclear. In a cohort of 476 adults and pediatric T-ALL, TP53Alt were observed in 4% of cases and were associated with chemoresistance and poor prognosis. APR-246, a small compound which restores wild-type configuration to mutated p53, showed efficacy in T-ALL harboring TP53 mutations. More importantly, in TP53 germline T-ALL, Notch 1 pathway gain of function mutations were associated with substantial sensitivity to APR-246. Mechanistically, Notch 1 activation via p53 downregulation and subsequent ferroptosis induction led to preferential APR-246 sensitivity. Given that Notch 1 pathway oncogenic activation is present in more than 70% of T-ALLs, these observations pave the way for promising perspectives in T-ALL treatment which could benefit from the Achilles heel associated with Notch 1 activation sensitizing leukemia cells to APR-246-induced ferroptosis, thus extending the use of APR-246 in T-ALL beyond TP53 alterations.

Classes IPC  ?

• A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to chemically modified adeno-associated (AAV) viruses and their use in gene therapy.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Classes IPC  ?

• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes

Abrégé

A device includes a magnetic tunnel junction; a conductive spacer with low spin-orbit coupling and high mean orbital moment diffusion length; and a conductive track able to generate an orbital moment current from a charge current and having a weak spin-orbit coupling.

Classes IPC  ?

• H10B 61/00 - Dispositifs de mémoire magnétique, p. ex. dispositifs RAM magnéto-résistifs [MRAM]
• H10N 50/01 - Fabrication ou traitement
• H10N 50/10 - Dispositifs magnéto-résistifs

Abrégé

The invention relates to a device for examining the anterior part of the eye by retro-illumination of said anterior part. This device has means for illuminating the eye, comprising a light source (1), and means for imaging the anterior part of the eye. The invention consists in the device further comprising means of modulating at least one region of the light beam emitted from the light source (1).

Classes IPC  ?

• A61B 3/15 - Dispositions spécialement adaptées à la photographie de l'œil avec des moyens d'alignement, d'espacement ou de suppression des réflexions parasites

Abrégé

The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and/or copper-associated disorders.

Classes IPC  ?

• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• C07D 209/16 - Tryptamines
• C07D 209/30 - IndolesIndoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone de l'hétérocycle
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Abrégé

The invention relates to a stator part (20) of a turbine engine, comprising a platform (22), a blade (24, 26) extending radially relative to a central axis (A), and a fin (28) extending radially from a fin root (44) to a fin tip (46), the fin comprising a lower side (48) and an upper side (50), each point (100) of the lower side or of the upper side defining a radial axis (Ar) passing through the point, each plane (Pr) that includes the radial axis defining a section (S) of the lower side or of the upper side, an angle defined in the plane between the root profile and a tangent to the section at an intersection (104) of the section and of the root profile being less than or equal to 45 degrees, the section being located between the root profile and the tangent.

Classes IPC  ?

• F01D 9/04 - InjecteursLogement des injecteursAubes de statorTuyères de guidage formant une couronne ou un secteur
• F01D 5/14 - Forme ou structure

Abrégé

Quantum emulator The present invention relates to a quantum emulator (10) for emulating the response of a quantum device to commands received by the quantum device, the quantum device comprising a system of quantum objects and a set of hardware elements for manipulating the quantum objects following the reception of commands by the quantum device, the hardware elements having imperfections impacting the manipulations, the quantum emulator (10) being configured to receive an input signal corresponding to a command intended to be sent to the quantum device in order to carry out a manipulation, and to compute an output signal corresponding to an emulated response of the quantum device, the quantum emulator (10) comprising a hardware module (32) configured to represent transfer functions taking into account an imperfection introduced by a hardware element.

Classes IPC  ?

• G06N 10/80 - Programmation quantique, p. ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiquesPlate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p. ex. informatique quantique en nuage

Abrégé

The present invention pertains to cell culture protocols and particularly provides a method for obtaining Invariant Natural Killer T (iNKT) cells. The method according to the present invention particularly comprises culturing peripheral blood mononuclear cells (PBMC) in a culture medium comprising alpha-Galactosylceramide (alpha-GalCer) and Interleukin 15 (IL-15). The present invention allows for the specific expansion of CD4V iNKT which have a particular interest in the prevention of graft versus host disease in the context of hematopoietic stem cell transplantation.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The invention relates to a microfluidic device (100) comprising at least one sheath fluid inlet channel (1, 2) and a sample fluid inlet channel (3), and a common channel (4) configured to guide the sample fluid (20), with hydrodynamic focusing, and the at least one sheath fluid (21, 22) in the direction of at least two outlet channels (11, 12, 13). The invention relates to a microfluidic device (100) comprising at least one sheath fluid inlet channel (1, 2) and a sample fluid inlet channel (3), and a common channel (4) configured to guide the sample fluid (20), with hydrodynamic focusing, and the at least one sheath fluid (21, 22) in the direction of at least two outlet channels (11, 12, 13). According to the invention, the microfluidic device comprises heating means arranged to transmit over a short period of time an amount of heat localised in the at least one sheath fluid flow (21, 22) in the common channel (4) upstream of a junction between the at least two outlet channels (11, 12, 13) and the at least one sheath fluid having a thermal variation in viscosity suitable for diverting or extracting a portion (120, 130, 220) of the sample fluid selectively towards a given outlet channel.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

The present invention relates to a fusion protein, to a nucleic acid coding for the protein, to a vector comprising the nucleic acid, to a host cell comprising the nucleic acid and/or vector, to a process for producing a fusion protein and to a process for bioconverting a substrate. The fusion protein of the present invention successively comprises (i) at least one polypeptide for targeting, and anchoring to, the bacterial membrane, (ii) at least one polypeptide corresponding to the hydrophilic domain of a plant P450 cytochrome, (iii) at least one binding polypeptide comprising at least 47 amino acids, and (iv) at least one polypeptide corresponding to the hydrophilic domain of a plant NADPH-dependent cytochrome P450 reductase.

Classes IPC  ?

• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli

Abrégé

A method for producing ammoniacal nitrogen by feeding an electrochemical cell with dinitrogen (N2), the electrochemical cell including at least one working electrode immersed in a composition including at least one compound (I) containing at least one element from group 13 of the periodic table, and at least one counter electrode; and an electrochemical cell for the reduction of dinitrogen into ammoniacal nitrogen.

Classes IPC  ?

• C25B 1/27 - Ammoniaque
• C25B 9/19 - Cellules comprenant des électrodes fixes de dimensions stablesAssemblages de leurs éléments de structure avec des diaphragmes
• C25B 11/043 - Carbone, p. ex. diamant ou graphène
• C25B 11/046 - Alliages

Abrégé

An ultrasound characterisation method of a medium comprising the steps of generating a series of incident ultrasound waves, measuring a canonical reflection matrix defined between the input emission base and an output reception base, determining a set of responses of the medium obtained from the canonical reflection matrix, at a plurality of frequencies and for several points in a region around a reference point, determination of a frequency correction law from the responses of the medium at the various points, the frequency correction law being adapted to the reference point and being determined at frequencies, determination of the corrected responses of the medium by applying the frequency correction law to the responses of the medium around the reference point and for the plurality of frequencies.

Classes IPC  ?

• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• G01S 7/52 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe

Abrégé

A sensor device including a conductive graphene film covered on at least one side by a graphene support layer of parylene, a detection element configured to sense an environmental change, and an electrode. The parylene repairs some defects of the conductive graphene film without damaging, polluting, or degrading the conductivity of conductive graphene film.

Classes IPC  ?

• C01B 32/186 - Préparation par dépôt chimique en phase vapeur [CVD]
• B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
• C01B 32/194 - Post-traitement
• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
• G06F 3/042 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens opto-électroniques

Abrégé

A sensor device including a conductive graphene film covered on at least one side by a graphene support layer of parylene, a detection element configured to sense an environmental change, and an electrode. The parylene repairs some defects of the conductive graphene film without damaging, polluting, or degrading the conductivity of conductive graphene film.

Classes IPC  ?

• C01B 32/186 - Préparation par dépôt chimique en phase vapeur [CVD]
• B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
• C01B 32/194 - Post-traitement
• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
• G06F 3/042 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens opto-électroniques

Abrégé

The device comprises a substrate comprising a first zone (1) on which is absorbed a protein capable of binding to a first membrane molecule and comprising a second zone (2), on which an antibody is absorbed, targeting a second membrane molecule, the first zone and the second zone extending together in length over a dimension comparable to the length of a cell.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Composition based on (meth)acrylate compounds Composition based on (meth)acrylate compounds The present invention relates to a crosslinkable two-component composition comprising: a component A comprising: an organocopper derivative; at least one (meth)acrylate compound M1; on condition that when the organocopper derivative is not halogenated, then component A also comprises a halogenated carboxylic acid; a component B comprising at least one compound having the formula (VI) below: Composition based on (meth)acrylate compounds The present invention relates to a crosslinkable two-component composition comprising: a component A comprising: an organocopper derivative; at least one (meth)acrylate compound M1; on condition that when the organocopper derivative is not halogenated, then component A also comprises a halogenated carboxylic acid; a component B comprising at least one compound having the formula (VI) below: Composition based on (meth)acrylate compounds The present invention relates to a crosslinkable two-component composition comprising: a component A comprising: an organocopper derivative; at least one (meth)acrylate compound M1; on condition that when the organocopper derivative is not halogenated, then component A also comprises a halogenated carboxylic acid; a component B comprising at least one compound having the formula (VI) below: and also to the uses thereof.

Classes IPC  ?

• C09J 133/14 - Homopolymères ou copolymères d'esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle
• C08F 120/16 - Esters des alcools ou des phénols monohydriques des phénols ou des alcools contenant plusieurs atomes de carbone
• C08F 120/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
• C09J 5/00 - Procédés de collage en généralProcédés de collage non prévus ailleurs, p. ex. relatifs aux amorces
• C09J 9/02 - Adhésifs conducteurs de l'électricité
• C09J 133/10 - Homopolymères ou copolymères d'esters de l'acide méthacrylique

Abrégé

The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed reduction chemical reactions, preferably of CO2 into small molecules. The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed reduction chemical reactions, preferably of CO2 into small molecules. The present invention relates to a new catalyst compound comprising at least a copper (Cu) layer, wherein the copper layer is functionalized with at least one aryl group and its use thereof in a reduction chemical reaction, preferably in reduction of CO2 into CO, ethylene and other small molecules such as gaseous hydrocarbons (methane, propane) or liquid molecules (ethanol, formic acid, propanol). The invention relates to the process of manufacture of said catalyst compound and to a process electrochemical conversion of CO2 to small molecules and in particular ethylene.

Classes IPC  ?

• C25B 11/052 - Électrodes comportant un substrat et un ou plusieurs revêtements électro-catalytiques
• C25B 11/032 - Électrodes à diffusion de gaz
• C25B 11/065 - Carbone
• C25B 11/095 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques au moins un des composés est de type organique

Abrégé

Hydraulic binder composition comprising: a mixture of (i) between 20 and 95 dry wt % of at least one steel making slag, (ii) between 4 and 79 dry wt % of at least a slag different from (i) and/or at least one pozzolanic material and/or at least one inert filler, and (iii) between 1 and 25 dry wt % of at least one co-binder; between 0.01 and 10 dry wt %, relative to the mixture total dry weight, of at least one steel making slag accelerator, between 0.1 and 5 dry wt %, relative to the mixture total dry weight, of at least one alkali activator for reacting (i), (ii), and/or (iii) with water, the alkali activator different from the slag accelerator and chosen among alkali mineral salts and mixtures thereof; and between 0.1 and 2 dry wt %, relative to the mixture total dry weight, of at least one fluidification agent.

Classes IPC  ?

• C04B 28/08 - Ciments de scories
• C04B 14/28 - Carbonates de calcium
• C04B 22/14 - Acides ou leurs sels comportant du soufre dans la partie anionique, p. ex. sulfures
• C04B 24/12 - Composés contenant de l'azote
• C04B 24/26 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
• C04B 103/10 - Accélérateurs
• C04B 103/32 - Superplastifiants

Abrégé

A plasma-enhanced deposition reactor including a reaction chamber including a plate having an upper face for receiving a substrate, a gas precursor inlet in the chamber, a pumping module of the chamber, a power source configured to apply a radio frequency bias to the plate, wherein a lateral wall of the chamber is at least partially non-parallel to the upper face of the plate, and the upper face of the plate and the lateral wall are separated by a distance d configured so as to generate a plasma by capacitive coupling between the plate and the lateral wall, the plasma is thus generated in a localised manner in the vicinity of the substrate with a low ion flux.

Classes IPC  ?

• H01J 37/32 - Tubes à décharge en atmosphère gazeuse
• C23C 16/458 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour supporter les substrats dans la chambre de réaction
• C23C 16/509 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement au moyen de décharges électriques utilisant des décharges à radiofréquence utilisant des électrodes internes

Abrégé

A substrate incouding a support of interest comprising a support layer and a buried oxide layer, a porous GaN or InGaN layer, a barrier layer, and an additional InGaN layer; and an electroluminescent diode including the substrate.

Classes IPC  ?

• H10H 20/815 - Corps ayant des structures de relaxation des contraintes, p. ex. des couches tampons
• H10H 20/01 - Fabrication ou traitement
• H10H 20/812 - Corps ayant des structures ou des superréseaux à effet quantique, p. ex. jonctions tunnel au sein des régions électroluminescentes, p. ex. structures de confinement quantique
• H10H 20/825 - Matériaux des régions électroluminescentes comprenant uniquement des matériaux du groupe III-V, p. ex. GaP contenant de l’azote, p. ex. GaN

Abrégé

The invention relates to a molecular complex emitting fluorescent light comprising, or consisting essentially of: ⋅—a fluorophore, and ⋅—a nucleic acid molecule, wherein said fluorophore has of the following formula 3 The invention relates to a molecular complex emitting fluorescent light comprising, or consisting essentially of: ⋅—a fluorophore, and ⋅—a nucleic acid molecule, wherein said fluorophore has of the following formula 3

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes

Abrégé

The disclosure relates to binding agents and compositions specifically binding the human Na+-taurocholate co-transporting polypeptide (NTCP/SLC10A1), thereby stabilizing a NTCP conformational state which allosterically inhibits its bile salt transport function. More specifically, the disclosure discloses Nanobodies that lock an inward-facing or open-pore NTCP conformational state, thereby useful as novel hepatitis virus B (HBV) and/or hepatitis virus D (HDV) antiviral, for treatment of liver disease, or as vehicle for targeted-delivery to the liver. Finally, the disclosure relates to a screening assay wherein said Nanobodies are used as a tool to identify NTCP conformation-selective compounds with therapeutic potential.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A plasma-enhanced atomic layer deposition method and the associated reactor, the method including a supply of a substrate into a plasma reactor including a reaction chamber, and a plurality of atomic layer deposition cycles on the exposed surface of the substrate, including an injection in the reaction chamber of a precursor based on a first species, a plasma treatment of the exposed surface of the substrate by a plasma by capacity coupling between the plate and the lateral wall of the reaction chamber, by applying a radiofrequency power to the plate. Capacitive coupling makes it possible to create a plasma localised in the vicinity of the substrate, at low and finely adjustable ion energy and density.

Classes IPC  ?

• C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
• C23C 16/458 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour supporter les substrats dans la chambre de réaction
• C23C 16/505 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement au moyen de décharges électriques utilisant des décharges à radiofréquence

Abrégé

A tracking system and a method for 3D tracking of a medical device, equipped of at least one ultrasound sensor, inside an anatomical region of a subject having at least one layer of a first tissue type at least partially surrounding a volume having at least one second tissue type, wherein the properties of ultrasounds propagation in the first and second tissue type are different.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

The invention relates to a fully humanized anti-HER2 single domain antibody (sdAb) and variants thereof. The present invention further relates to nucleic acids, vectors, host cells, immune cells, functionalized drug nanocarriers comprising said sdAb, and compositions comprising thereof. The invention also relates to therapeutic and diagnostic uses thereof and to methods and pharmaceutical compositions for the treatment of cancer. The invention also relates to chimeric antigen receptors including said humanized HER2 sdAb in their antigen binding domain and their use in cancer cell therapy.

Classes IPC  ?

• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a stator part (20) comprising a platform (22), a first blade (24), a second blade (26), and a fin (28) having a leading edge (30) and a trailing edge (32), the fin extending opposite an upper surface (124) of the first blade and a lower surface (126) of the second blade, the leading edge comprising a leading point (34) located on the platform, a tangent to the leading edge at the leading point extending between the first blade and a radial leading plane (Pa) and the leading point, and the trailing edge comprising a trailing point (36) located on the platform, a tangent to the trailing edge at the trailing point extending between the second blade and a radial trailing plane (Pf) and the trailing point.

Classes IPC  ?

• F01D 9/04 - InjecteursLogement des injecteursAubes de statorTuyères de guidage formant une couronne ou un secteur
• B64D 27/10 - Aéronefs caractérisés par le type ou la position des groupes moteurs du type à turbine à gaz
• F01D 5/14 - Forme ou structure

Abrégé

The invention relates to a non-destructive inspection method based on 3D modelling of a part, comprising: using an x-ray device to acquire images of the part at various projection angles; computing projections based on the images acquired at the various projection angles; in each of multiple iterations: generating simulated projections corresponding to the computed projections, based on a reference model of an external surface of the part and on a vector μ of transformation parameters of the reference model; modifying the vector μ with a view to reducing a discrepancy between the simulated projections and the computed projections; determining a corrected model of the external surface through transformation of the reference model by way of the vector μ resulting from the iterations; determining an effective model of the part by way of the corrected model.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
• G01N 23/083 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et mesurant l'absorption le rayonnement consistant en rayons X
• G06T 15/08 - Rendu de volume
• G06T 15/20 - Calcul de perspectives

Abrégé

An elastography apparatus is described that is designed to assist in magnetic resonance elastography of the head of an examination object. The elastography apparatus comprises a first support element which is designed to be positioned within a radiofrequency receiving coil unit and a vibration generator which is designed to generate mechanical waves. The first support element has a first recess for receiving the vibration generator, the first support element has a second recess for receiving the head, and the first recess is so shaped as to at least partially enclose the vibration generator in a custom-fit manner and the vibration generator is arranged at least partially within the first recess.

Classes IPC  ?

• G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique

Abrégé

The invention relates to a chimeric protein comprising three covalently linked domains including a RNA-guided DNA endonuclease, a flexible peptide linker, and a switchable receptor binding domain. The endonuclease activity depends on the uncaging of a caged specific ligand of said switchable receptor binding domain. Methods for inducing nuclear translocation of the chimeric protein and inducing the modification of an endogenous gene in a eukaryotic cell are also disclosed.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
• C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p. ex. par magnétisme, par des ondes sonores
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

Disclosed is a composition comprising 70 to 95 parts by mass of an epoxy resin with a viscosity of less than or equal to 20 Pa·s, for example between 1 and 20, or between 1 and 10, at a temperature of between 20° C. and 25° C., and 5 to 30 parts by mass of a hardener dispersed in the resin, per 100 parts by mass of resin present in the composition, wherein the hardener is an ionic liquid containing a phosphonium cation of formula P(R1R2R3R4)+ wherein R1, R2, R3 and R4, which may be identical or different, represent a hydrogen atom, an alkyl radical having 1 to 18 carbon atoms, an aryl radical having 6 to 20 carbon atoms, said alkyl and aryl radicals being optionally substituted, and an acetate anion of formula (R5CO2)− wherein R5 represents a hydrogen atom, an alkyl radical having 1 to 18 carbon atoms, an aryl radical having 6 to 20 carbon atoms, said alkyl and aryl radicals being optionally substituted, or a phosphinate anion of formula [[(CH3)3CCH2CH(CH3)CH2]2P(O)O]−. Further disclosed is the use of a composition for the manufacture of a hydrogen vessel, in particular a vessel operating under pressure, of types II, III, IV and V, comprising a composite material, for the on-board storage of gaseous hydrogen.

Classes IPC  ?

• C08G 59/40 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les agents de durcissement utilisés
• B29B 11/16 - Fabrication de préformes caractérisées par la structure ou la composition comprenant des charges ou des agents de renforcement
• B29K 63/00 - Utilisation de résines époxy comme matière de moulage
• B29K 105/06 - Présentation, forme ou état de la matière moulée contenant des agents de renforcement, charges ou inserts
• C08J 5/24 - Imprégnation de matériaux avec des prépolymères pouvant être polymérisés en place, p. ex. fabrication des "prepregs"
• F17C 1/16 - Récipients sous pression, p. ex. bouteilles de gaz, réservoirs de gaz, cartouches échangeables en matériaux plastiques

Abrégé

The invention concerns an ettringitic and stratlingitic binder composition comprising: A) Crystaline calcium aluminate Cement (CAC), B) Ground Granulated Blast Furnace Slag (GGBS), and C) Sulfate source selected from the group consisting of Anhydrite calcium sulfate (AC$) and/or alkali sulfate (A$).

Classes IPC  ?

• C04B 28/16 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p. ex. contenant des ciments de polycarboxylates contenant des ciments de sulfate de calcium contenant de l'anhydrite
• C04B 7/21 - Leurs mélanges avec d'autres matières inorganiques cimentaires ou avec d'autres activateurs avec des activateurs contenant du sulfate de calcium
• C04B 7/32 - Ciments alumineux
• C04B 11/06 - Ciments de sulfate de calcium à partir de l'anhydrite
• C04B 28/06 - Ciments alumineux
• C04B 111/00 - Fonction, propriétés ou utilisation des mortiers, du béton ou de la pierre artificielle
• C04B 111/60 - Revêtements de sol
• C04B 111/72 - Compositions utilisées pour réparer les bâtiments existants ou les matériaux de construction existants

Abrégé

Methods for preparing at least one glycolipid of formula (I): [Glc]n-xOy-R (I), with [Glc]n representing an osidic motif comprising 1-7 n glucosyl units; R representing a fatty acid radical with 4-24 carbon atoms; -xOy- symbolizing the attachment of the fatty acid radical to the osidic motif; the method comprising glucosylating a hydroxylated fatty acid of formula (II): R-yOH (II), where -yOH is a hydroxyl group attached to a carbon atom Cy; bringing the hydroxylated fatty acid of formula (II) into contact with at least one α-transglucosylase of the GH70 family in the presence of saccharose or a saccharose analogue.

Classes IPC  ?

• C12P 19/44 - Préparation d'O-glucosides, p. ex. glucosides
• A01N 25/04 - Dispersions ou gels
• A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
• A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
• C12N 9/10 - Transférases (2.)

Abrégé

The invention relates to a bioreactor cell culture system comprising a closed chamber containing a plurality of suspended cell microcompartments, wherein the microcompartments each comprise an outer hydrogel layer providing a cavity containing a set of self-organized cells and extracellular matrix or an extracellular matrix substitute. The invention further relates to the use of such bioreactors in methods for producing cells and/or organoids, and/or molecules and/or complex molecular assemblies.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
• C12N 1/04 - Conservation des micro-organismes à l'état viable

Abrégé

A bioconjugate including a photosensitizer unit, in particular a phthalocyanine unit, and an elastin-like polypeptide conjugated thereto, the elastin-like polypeptide containing at least one occurrence of a monomeric unit having the formula Xaa1PXaa2Xaa3G, wherein P represents a prolyl residue, G represents a glycyl residue, Xaa2 represents a glycyl residue or an alanyl residue and either Xaa1 represents a valyl residue and Xaa3 represents a sulfur-containing amino acid residue having a side chain of formula —(CH2)z—S—R′ or Xaa3 represents a valyl residue and Xaa1 represents a sulfur-containing amino acid residue having a side chain of formula —(CH2)z—S—R′. This bioconjugate proves particularly useful for the treatment of diseases by photodynamic therapy.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif

Abrégé

The invention relates to an engineered DNA polymerase D (PolD) and its use for nucleic acid amplification including reverse transcription of RNA.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques

Abrégé

A three-dimensional transformable structure containing a set of individual elementary components, so-called IECs, forming a single-piece assembly. An IEC includes an active or inert material and at least one portion of the set of IECs includes at least three connecting means. Each connecting means of a considered IEC is arranged to cooperate with at least one connecting means of an IEC adjacent to the considered IEC to connect the considered IEC to the adjacent IEC. For the at least one portion of the set of IECs, at least one of the connecting means of a given IEC is located on a side opposite to at least another one of the connecting means of the considered IEC. At least one portion of the set of IECs includes so-called “active” IECs spatially arranged in the transformable structure so that at least one property of the transformable structure is modified in response to the application of at least one stimulus.

Classes IPC  ?

• F16B 1/00 - Dispositifs pour assembler des éléments structuraux ou parties de machines ou bien pour empêcher tout mouvement relatif entre eux
• A63H 33/06 - Blocs, bandes ou autres éléments pour les jeux de construction assemblés sans emploi de pièces additionnelles
• B33Y 80/00 - Produits obtenus par fabrication additive

Abrégé

The present invention relates to the field of enzymology. More particularly, the present invention relates to a novel enzyme having a dual myeloperoxidase-catalase activity, and applications thereof.

Classes IPC  ?

• C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
• A01N 37/46 - Dérivés N-acylés
• C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)

Abrégé

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present disclosure relates to a method of performing 3D Magnetic Resonance Imaging including applying a magnetic gradient field that causes a concomitant field Bc. A further step of the method includes determining phase accruals due to the self-squared terms of the concomitant field Bc and phase accruals φxz, φyz due to the cross terms of the concomitant field Bc based on an encoding matrix that accounts for the different possible sign combinations of the applied magnetic gradients.

Classes IPC  ?

• G01R 33/565 - Correction de distorsions d'image, p. ex. dues à des inhomogénéités de champ magnétique
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G01R 33/385 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des bobines de champ magnétique à gradient

Abrégé

A method of making of an optical device provided with a nano-structured or micro-structured component assembled on one end of an optical fibre includes providing a carrier based on a material photosensitive and transformable into a vitreous material, and making on a first end of the carrier, by two-photon photopolymerization, a micro-structured or nano-structured component, based on a material photosensitive and transformable into a vitreous material. The method also includes performing one or more heat treatment(s) so as to transform the material of the carrier and the material of the micro- or nano-structured component into a vitreous material and, then, assembling and securing a region of a second end of the carrier opposite to the first end with an area of an end of the optical fibre, by localised fusion of the region and the area, respectively of the carrier and the optical fibre.

Classes IPC  ?

• B29D 11/00 - Fabrication d'éléments optiques, p. ex. lentilles ou prismes
• B29K 509/00 - Utilisation de matériaux inorganiques non prévus dans les groupes comme matière de remplissage

Abrégé

In a method for performing Magnetic Resonance Elastography (MRE) more efficiently may include providing a periodical vibration signal for exciting mechanical vibrations within an object to be examined with a vibration period, sampling the vibration signal with a sampling period corresponding to a natural number including zero of vibration periods plus a fixed time delay, and performing three motion encoding gradients for magnetic resonance acquisition in each sampling period. The fixed time delay multiplied with a sampling number may be equal to the vibration period. The sampling number may be a natural number greater than two.

Classes IPC  ?

• G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne

Abrégé

The use of hydronium ion-conducting amyloid fibers or of wires comprising a plurality of hydronium ion-conducting amyloid fibers for generating electrical energy from a humid surrounding atmosphere. The invention also relates to a device comprising such fibers or wires.

Classes IPC  ?

• H02N 11/00 - Générateurs ou moteurs non prévus ailleursMouvements dits perpétuels obtenus par des moyens électriques ou magnétiques

Abrégé

A method for forming a layer based upon a dielectric material on a layer based upon an etched III-V material includes providing at least one III-V layer base upon a III-V material, preferably III-N, having a front face. The method also includes etching at least one part of the III-V layer from the front face, so as to expose an etched surface of the III-V layer; exposing at least the etched surface to a plasma treatment of O2 or of N2, this step being carried out at a temperature Ttreatment with Ttreatment<100° C., and depositing a layer based upon a dielectric material at least on the etched surface.

Classes IPC  ?

• H10H 20/01 - Fabrication ou traitement
• H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives

Abrégé

Copper chelators of the tetradentate monoquinoline (TDMQ) series are highly efficient against several cancer cell lines. One of these selective copper chelators, TDMQ20, is highly cytotoxic on the non-small cell lung carcinoma (A549), the cervix cancer HeLa and the hepatocarcinoma HepG2 cell cultures, with IC50 values ranging from 14 to 16 μM in vitro, lower than those obtained with the reference drug 5-fluorouracil (5-FU). TDMQ20 also exhibits a significant antiproliferative activity on HeLa cells in vitro. The mechanism of its cytotoxicity and antiproliferative activity involved intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of apoptosis. The selectivity of TDMQ20 for cancer cells with respect to non-cancer human cells is higher than that of 5-FU, the reference drug. These data strongly support the selection of TDMQ20 as drug-candidate to treat several human cancers.

Classes IPC  ?

• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile

Abrégé

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

Classes IPC  ?

• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/08 - AntiépileptiquesAnticonvulsivants

Abrégé

This relates to a cell for a power generation device, which includes: —two compartments intended respectively to receive fluids that each have a different concentration of a predetermined ion, which compartments are separated by a membrane allowing the predetermined ion to pass through; and —two adsorbent layers of the predetermined ion placed respectively on either side of the membrane. The invention also relates to two power generation devices incorporating such a cell, and to a method for operating one of these devices.

Classes IPC  ?

• H01M 8/18 - Éléments à combustible à régénération, p. ex. batteries à flux REDOX ou éléments à combustible secondaires
• H01M 8/0202 - CollecteursSéparateurs, p. ex. séparateurs bipolairesInterconnecteurs
• H01M 8/0289 - Moyens pour maintenir l’électrolyte

Abrégé

The invention provides human phagocytic cells which are not tumorigenic, yet still capable of cell division ex-vivo, such as in cell culture. A culture containing these cells can be expanded manyfold, that is the cell number in such a culture can be increased by a factor of 10 or more. The cells show characteristics of functional phagocytes in a differentiated state and are capable to alleviate pathological defects in in vivo models.

Classes IPC  ?

• C12N 5/0786 - MonocytesMacrophages
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 40/17 - MonocytesMacrophages
• A61K 40/24 - Cellules présentatrices d’antigènes [APC]
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/074 - Cellules souches adultes

Abrégé

The invention relates to a microfluidic device (1) comprising a frame (32) and two opposite walls (16a,b), the two opposite walls (16a,b) and the frame (32) delimiting together a chamber (2): —the chamber (2) comprising a first zone (4) and a second zone (5), —the second zone (5) comprising a porous member (3) extending in the chamber (2) and comprising a first surface (9) and a second surface (10) opposite to the first surface (9), the first surface (9) separating the chamber (2) in the first zone (4) and in the second zone (5), —the frame (32) comprising at least a first and a second sets of ports (11, 12, 13, 14), the first set of port comprising at least two ports (11, 12) arranged in the frame (32) for fluid circulation within in the first zone (4) and the second set of ports comprising at least two ports (13, 14) arranged in the frame (32) for fluid circulation within the second zone (5), and—the two ports (13, 14) of the second set of ports being open (i) in a microchannel (15) extending through the porous member (3), or (ii) in a cavity (19) arranged between the second surface (10) of the porous member (3) and the frame (32) of the chamber (2). The invention relates to microphysiological systems comprising a microfluidic device and cultured cells on the top surface of the hydrogel matrix. The microphysiological systems may be used to model biological surface or biological tissue at physiological interface comprising a luminal and a stromal compartments, such as colon, pancreas or skin tissue.

Classes IPC  ?

• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse

Abrégé

The invention concerns a method for separating at least one rare earth element from a solution containing said at least one rare earth element and optionally at least one further magnetic element, the method comprising the following steps a) applying to the solution a non-uniform magnetic field, whereby creating within the solution at least one first zone and at least one second zone having a different magnetic field value, the application of the non-uniform magnetic field value inducing concentrating said at least one rare earth element in the first zone and concentrating said optional at least one further magnetic element in the second zone, b) increasing the pH of the solution in the first zone, to precipitate said at least one rare earth element, or in the second zone to precipitate said optional at least one further magnetic element, and c) recovering the precipitate.

Classes IPC  ?

• B03C 1/025 - Séparateurs magnétiques à gradient de champ élevé
• B03C 1/28 - Bouchons et jauges magnétiques
• C22B 3/22 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques
• C22B 3/44 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés chimiques
• C22B 59/00 - Obtention des métaux des terres rares

Abrégé

The present invention concerns a method for characterizing a geological reservoir of interest, the method comprising the training of an artificial intelligence model according to a training technique applied to a training database to obtain a trained model, the trained model predicting the spatiotemporal evolution over a period of time of flow parameter(s) for a geological reservoir of interest when a set of input data relative to the geological reservoir of interest are inputted in the trained model, the set of input data comprising initial values of each flow parameter for the geological reservoir of interest and values of geological features for said geological reservoir of interest, the artificial intelligence model being a neural network having neural parameters.

Classes IPC  ?

• G01V 20/00 - Géomodélisation en général
• G06F 30/27 - Optimisation, vérification ou simulation de l’objet conçu utilisant l’apprentissage automatique, p. ex. l’intelligence artificielle, les réseaux neuronaux, les machines à support de vecteur [MSV] ou l’apprentissage d’un modèle

Abrégé

The present application concerns the use of endoprothesis covalently grafted with a fucoidan for treating aneurysms, in particular cerebral aneurysms, and their process for manufacturing the same. Improved healing of cerebral aneurysms was established in vivo on a rabbit model.

Classes IPC  ?

• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61L 31/02 - Matériaux inorganiques
• A61L 31/10 - Matériaux macromoléculaires
• C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou

Abrégé

The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Multiple Myeloma (MM). A pharmaceutical composition including a pharmaceutical acceptable vehicle and at least a compound of formula (I) is also included.

Classes IPC  ?

• A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
• A61K 31/4433 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 38/07 - Tétrapeptides
• A61P 35/00 - Agents anticancéreux
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

A method is disclosed for treating an individual afflicted by a multiple myeloma by a composition comprising at least one G-quadruplex (G4) stabilizer. Also disclosed is a composition comprising at least one G-quadruplex (G4) stabilizer for its use in a method for treating an individual afflicted by a multiple myeloma.

Classes IPC  ?

• A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to the combination of a miR-17mimic and a miR-340 mimic for use for the prevention and/or treatment of cancer, in particular for the treatment of glioblastoma. In particular, said combination additionally comprises a miR-222 antagomiR.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a compound of formula (I) and its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/13 - Lymphocytes B
• A61P 37/02 - Immunomodulateurs
• C07D 471/04 - Systèmes condensés en ortho
• C12N 5/0781 - Cellules BLeurs progéniteurs

Abrégé

The invention relates to a module intended to be associated with a microscope for full-field optical coherence tomography microscopic imaging of at least one sample, the module comprising an interference device (4) comprising a non-polarising beam splitter element (10) for forming two arms when it is illuminated by a source, namely a “reference arm” associated with the reflection surface and an “object arm” associated with the sample, the device furthermore comprising: a first adjustment unit (11) arranged upstream of the non-polarising beam splitter element for allowing an illumination arm of the non-polarising beam splitter element to be modified during operation, and/or at least one second adjustment unit (18) arranged between the beam splitter element and the reflection surface for allowing the reference arm to be modified during operation.

Classes IPC  ?

• G02B 21/18 - Aménagements avec plus d'un parcours de lumière, p. ex. pour comparer deux échantillons
• G02B 21/02 - Objectifs
• G02B 21/24 - Structure du bâti ou statif
• G02B 21/26 - PlatinesMoyens de réglage pour celles-ci

Abrégé

A compound of Formula (I): A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(═O)—R1, —NR1—C(═O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(═O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R′ is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(═O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(═O)—R1, —NR1—C(═O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(═O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R′ is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(═O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R′, n, and n′ are as described above.

Classes IPC  ?

• A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 9/12 - Antihypertenseurs

Abrégé

The two nucleoredoxin genes, NXNL1 and NXNL2 encode by alternative splicing for a secreted truncated thioredoxin that mediates neuronal survival and a thioredoxin enzyme that regulates the phosphorylation of TAU. Behavioral analyses of young Nxnl2−/− mice demonstrate that this gene is involved in regulating of brain functions and is essential for learning and memory exerting positive effects on long-term potentiation (LTP) in the hippocampus. LTP dysfunction on the young Nxnl2−/− mice can be fully corrected by the synergistic action of the two products of the Nxnl2 gene. Aging Nxnl2−/− mice have brain stigmata of tauopathy as seen by oligomerization, phosphorylation and aggregation of TAU. This late occurring tauopathy can be prevented, by recombinant AAVs encoding RdCVF2 and RdCVF2L when administrated to young animals, which is of significant interest for therapeutic perspectives. Therefore, the present invention relates to a method of treating a tauopathy in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a first polynucleotide encoding for the short isoform of the NXNL2 gene. Rod-derived Cone Viability Factor (RdCVF2) and of a second polynucleotide encoding the long isoform of the NXNL2 gene, RdCVF2L.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12N 15/86 - Vecteurs viraux

Abrégé

Provided herein are methods of generating a trained classifier at least partially using a computer. The methods include training a Restricted Boltzmann Machine (RBM) using at least a first training dataset that comprises sequence information corresponding to a population of aptamers, and/or one or more descriptors thereof, which aptamers comprise a minimum threshold binding affinity to a target biomolecule to produce a trained RBM model. Additional methods as well as related systems and computer readable media are also provided.

Classes IPC  ?

• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• G06N 3/047 - Réseaux probabilistes ou stochastiques
• G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire

Abrégé

A cathode for a lithium-ion battery including a layer of a conductive material arranged to collect the current flowing through the cathode, which layer is referred to as the substrate of the cathode, a layer of aligned carbon nanotubes (CNTs) in electrical contact with the substrate of the cathode and mainly extending perpendicular to the substrate of the cathode, solid sulfur which at least partially coats an outer wall of the CNTs and a solid layer of solid lithium sulfate (Li2SO4), which layer is referred to as the outer layer of Li2SO4, covering the layer of CNTs so as to form a stack of layers in which the layer of CNTs is located between the substrate of the cathode and the outer layer of Li2SO4 is disclosed.

Classes IPC  ?

• H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
• H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
• H01M 4/04 - Procédés de fabrication en général
• H01M 4/134 - Électrodes à base de métaux, de Si ou d'alliages
• H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
• H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/058 - Structure ou fabrication

Abrégé

The disclosure relates to an automated system for processing physiological parameter measurements for providing a medical risk assessment, wherein it comprises: a module for receiving physiological parameter measurements (p1 . . . p15) for a female to be assessed; and a module for calculating a nonclassical 21-hydroxylase deficiency score (SNC21OHD) for the female to be assessed, according to a model which gives the score (SNC21OHD) on the basis of the measurements (p1 . . . p15) received. The physiological parameters comprise at least the following steroids: 21-deoxycortisol; 21-deoxycorticosterone; 11β-hydroxyandrostenedione; 17-OH-progesterone; androstenedione; corticosterone; and testosterone.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

Abrégé

A device for receiving radio frequency signals for a magnetic resonance imaging/spectroscopy system including an intracardiac receiving resonant loop and a switch capable of being alternately in an open state such that the frequency of the receiving antenna is tuned to an operating frequency of the magnetic resonance imaging system, and in a closed state such that the frequency of the receiving resonant loop is detuned, the receiving device including a first transmission line having a conductor with a distal end electrically connected to the receiving resonant loop and a proximal end electrically connected to the switch such that the switch is intended to be located outside the human body when the receiving resonant loop is located inside a patient's heart.

Classes IPC  ?

• G01R 33/36 - Détails électriques, p. ex. adaptations ou couplage de la bobine au récepteur
• G01R 33/28 - Détails des appareils prévus dans les groupes
• G01R 33/34 - Détails de structure, p. ex. résonateurs

Abrégé

The invention relates to the use of a SQSTM1/p62 protein for modulating and predicting the response to: —an immunotherapy against immune checkpoint inhibitors: or—a combination of an immunotherapy, preferably an ICI, and a chemotherapy

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The invention relates to an aqueous lubricant composition comprising at least: —water; —at least one polyalkylene glycol; —at least one antifreeze compound selected from glycols, preferably alkylene glycols; glycerol; diglycerol; triglycerol, and mixtures thereof; —at least one ascorbic acid ester; and —at least one pH-regulating additive, making it possible to maintain the pH of said lubricant composition between (8) and (15). It also relates to the use of such an aqueous lubricant composition, for lubricating and/or cooling the moving parts in a mechanical system or as a hydraulic fluid. The invention also relates to the use of at least one ascorbic acid ester as an additive for improving the tribological properties of an aqueous lubricant composition.

Classes IPC  ?

• C10M 173/02 - Compositions lubrifiantes contenant plus de 10% d'eau ne contenant pas d'huiles minérales ou grasses
• C10M 107/34 - Polyoxyalkylènes
• C10M 129/16 - Éthers
• C10M 129/76 - Esters contenant des groupes hydroxyle ou carboxyle libres
• C10M 133/08 - Amines, p. ex. polyalkylènepolyaminesAmines quaternaires comportant des groupes amine liés à des atomes de carbone acycliques ou cycloaliphatiques contenant des groupes hydroxyle
• C10M 141/06 - Compositions lubrifiantes caractérisées en ce que l'additif est un mélange d'au moins deux composés couverts par plus d'un des groupes principaux , chacun de ces composés étant un composé essentiel l'un d'eux, au moins, étant un composé organique contenant de l'azote
• C10N 40/08 - Fluides hydrauliques, p. ex. fluides pour freins

Abrégé

The present invention is drawn to an algorithm and method using the same algorithm for in vitro predicting the probability of a drug or a compound to induce a particular effect in a patient, said method using at least one target exhibiting an A-to-I editing of RNA. The present invention also relates to kits for the implementation of the method.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
• G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p. ex. relations structurelles ou fonctionnelles ou alignement de structures
• G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
• G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
• G16B 50/00 - TIC pour la programmation d’outils ou de systèmes de bases de données spécialement adaptées à la bio-informatique

Abrégé

Nowadays, the interest to use ultrasound waves in medical field is well established. Indeed, the study of mechanical waves propagating in a medium allows usually to retrieve the properties of this medium as an organ such the heart. These elastic properties may be determined on the basis of propagation parameters as the velocity of shear waves propagating in the medium. The shear waves may be generated artificially or naturally (e.g. valves closure of the heart) in the medium. In both cases, the generation or/and observation of such shear waves require high complex and cost system as well as complex method for estimating with high precision the velocity of shear. The present disclosure overcomes the above drawbacks by proposing a new method and detection system for estimating in a simple and efficiency way the velocity of shear waves propagating in a medium, and with a high precision, requirement needed for determining the elastic properties of the medium.

Classes IPC  ?

• G01N 29/07 - Analyse de solides en mesurant la vitesse de propagation ou le temps de propagation des ondes acoustiques
• G01N 29/44 - Traitement du signal de réponse détecté
• G01S 7/52 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation

Abrégé

The present invention relates to variants of acid-alpha glucosidase and uses thereof.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61K 35/34 - MusclesCellules musculaires lissesCœurCellules souches cardiaquesMyoblastesMyocytesCardiomyocytes
• A61K 35/407 - FoieHépatocytes

Abrégé

The use of a composition including at least one compound derived from cashew nut shell oil (CNSL), which has at least one ester function and/or at least one epoxide function, as a plasticizing agent for cellulose acetate, for the preparation of a plastic material including or solely composed of cellulose acetate.

Classes IPC  ?

• C08J 3/18 - Plastification de composés macromoléculaires
• C07C 67/08 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec le groupe hydroxyle ou O-métal de composés organiques
• C07D 303/42 - Composés acycliques comportant une chaîne d'au moins sept atomes de carbone, p. ex. corps gras époxydés
• C08J 5/18 - Fabrication de bandes ou de feuilles
• C08K 5/134 - Phénols contenant des groupes ester
• C08K 5/1515 - Cycles à trois chaînons

Abrégé

A method for use in the treatment of diseases affecting the brain by providing exogenous Nav1.1 via CAV-2 vector-mediated delivery of a copy of SCNIA ORF into central nervous system (CNS) neurons. The method includes injection of the viral vector into the hippocampus and/or thalamus. Transcriptional control of the SCNIA expression cassette can be provided by specific promoters, such as NSE, to achieve targeted neuronal expression. This strategy is suitable as a therapeutic approach regardless of the underling SCNIA mutation. Moreover, because this approach compensates for the loss of function of Nav1.1, it can potentially ameliorate Dravet Syndrome, epileptic and non-epileptic comorbidities thereof, epilepsy, Alzheñner's, and other Nav1.1-associated pathological conditions.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.

Classes IPC  ?

• A01N 1/143 - Appareils pour la perfusion d'organes

Abrégé

The invention concerns a computer-implemented method for compressing a neural network comprising neurons and synapses interconnecting the neurons, the method being implemented by a compressing device and comprising: determining, for each synapse of a plurality of synapses of the neural network, a capacity representative of a level of influence of a synaptic weight assigned to the synapse, the capacity being determined as a function of the synaptic weight and as a function of data exchanged through the synapse; and pruning one or more synapses of the plurality of synapses, as a function of the determined capacity of each of the one or more synapses.

Classes IPC  ?

• G06N 3/0495 - Réseaux quantifiésRéseaux parcimonieuxRéseaux compressés
• G06N 3/082 - Méthodes d'apprentissage modifiant l’architecture, p. ex. par ajout, suppression ou mise sous silence de nœuds ou de connexions

Abrégé

Lung cancer is the leading cause of cancer deaths worldwide. Metastatic non-small-cell lung cancer (NSCLC) has recently benefited from two consecutive breakthroughs: the identification of oncogene drivers, such as KRAS mutations, leading to the development of targeted therapies, and the understanding of the cancer immunity cycle leading to the development of immune checkpoint inhibitors. KRASG12C mutations can be found in approximately 13% of patients with non-small-cell lung cancer (NSCLC) and historically have been associated with a poor prognosis. Now, data from a phase II trial demonstrate the efficacy of the novel KRASG12C-specific inhibitor sotorasib for patients with advanced-stage NSCLC harbouring this alteration with disease progression on at least one standard-of-care therapy. However one could expect that resistance to Ras inhibitors could occur and that there is a need for identifying new therapeutic avenues for limiting said resistance. The inventors now show that when use alone, sotorasib and tipifarnib did not show a significant anti-tumor effect on lung cancer cells harboring the G12C KRAS mutation, whereas the combination potently induced cell death, suggesting a synergism between these drugs. The present invention thus relates to the combination of Ras inhibitors and famesyltransferase inhibitors for the treatment of cancers.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to an aqueous lubricant composition comprising at least: —water; —at least one polyalkylene glycol; —at least one antifreeze compound selected from glycols, preferably alkylene glycols; glycerol; diglycerol; triglycerol, and mixtures thereof; —at least one gallic acid ester; and—at least one pH-regulating additive, making it possible to maintain the pH of said lubricant composition between (8) and (15). It also relates to the use of such an aqueous lubricant composition, for lubricating and/or cooling the moving parts in a mechanical system or as a hydraulic fluid. The invention also relates to the use of at least one gallic acid ester as an additive for improving the tribological properties of an aqueous lubricant composition.

Classes IPC  ?

• C10M 173/02 - Compositions lubrifiantes contenant plus de 10% d'eau ne contenant pas d'huiles minérales ou grasses
• C10M 107/30 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
• C10M 129/16 - Éthers
• C10M 129/76 - Esters contenant des groupes hydroxyle ou carboxyle libres
• C10M 133/08 - Amines, p. ex. polyalkylènepolyaminesAmines quaternaires comportant des groupes amine liés à des atomes de carbone acycliques ou cycloaliphatiques contenant des groupes hydroxyle
• C10M 141/06 - Compositions lubrifiantes caractérisées en ce que l'additif est un mélange d'au moins deux composés couverts par plus d'un des groupes principaux , chacun de ces composés étant un composé essentiel l'un d'eux, au moins, étant un composé organique contenant de l'azote
• C10N 40/04 - Bains d'huileBoîtes de vitessesTransmissions automatiquesMécanismes de traction
• C10N 40/08 - Fluides hydrauliques, p. ex. fluides pour freins

Abrégé

A method of screening of at least one phenotype or biological process, for example, self-replicating ability of microbial cells, in a high throughput droplet micro- to milli-fluidic system, based on the use of a photoconvertible or a photoactivable fluorescent protein and artificial intelligence to allow automated imaging and selection.

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes

Abrégé

The present disclosure relates to compositions comprising collagen microparticles comprising more than 90% by weight of collagen, biomimetic hydroxyapatite or biomimetic hydroxyapatite precursors and a physiologically compatible aqueous solvent for use in dentine repair.

Classes IPC  ?

• A61K 6/75 - Apatite
• A61K 6/17 - Taille des particules
• A61K 6/60 - Préparations pour la technique dentaire comprenant des additifs organiques ou organométalliques

Abrégé

A system for surface treatment of materials, including a target material, at least one transfer device and at least one plasma generator device. The plasma generator device includes a fluid (formula B) and generates a column of cold plasma. The target material is able to travel a path between a starting point and an end point, passing through the plasma generator device and the plasma column, along a unit vector of movement. The transfer device includes a fluid (formula A) transferred from the transfer device to the plasma generator device. The plasma column, generated from the fluids (formula A) and (formula B), has an oblong geometric shape of length (formula C), according to a longitudinal axis colinear with the vector of movement, and of width (formula D), according to a transverse axis perpendicular to the vector of movement, such that (formula E).

Classes IPC  ?

• H01J 37/30 - Tubes à faisceau électronique ou ionique destinés aux traitements localisés d'objets
• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériauMoyens de réglage de diaphragmes ou de lentilles associées au support

Abrégé

Despite aggressive radio/chemotherapy regimens, pediatric high-grade gliomas (pHGG) are deadly brain tumors that remain incurable and are the leading cause of cancer-related death in children. By analysing the impact of H3.3 mutations on DNA repair and genome integrity maintenance capacities of glioma cells, the present inventors identified the PNKP enzyme as being a major protein partner interacting with mutated H3 oncohistone specifically, and involved in DNA aberrant repair. They showed that inhibition of this enzyme prevents the proliferation of glioma tumor cells bearing specific H3 oncohistone mutations. They therefore propose to target this enzyme in order to efficiently treat patients suffering from gliomas, in particular pediatric gliomas bearing these specific H3 oncohistone mutations, or to sensitize them to current radio/chemotherapeutic regimens, for which there is very limited response.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

A method for protection against oxidation of a composite material part includes carbon, the method including impregnating an internal porosity of the part with an impregnation composition including, as percentages by weight: (i) between 1% and 60% of colloidal silica; (ii) between 0.5% and 20% of a flux precursor including at least one nitrate of an alkali metal Ml; (iii) between 0.5% and 20% of a lattice modifying precursor, including at least one nitrate or one oxynitrate of an element M2 which is chosen from metals or lanthanides; and (iv) between 20% and 88% of water; and carrying out a vitrification heat treatment on the part impregnated with the impregnation composition so as to obtain a glass for protection against oxidation including at least silica, an oxide of M1 and an oxide of M2.

Classes IPC  ?

• F16D 69/02 - Composition des garnitures
• C03B 32/00 - Post-traitement thermique des produits vitreux non prévu dans les groupes , p. ex. cristallisation, élimination des inclusions gazeuses ou autres impuretés
• C03C 3/078 - Compositions pour la fabrication du verre contenant de la silice avec 40 à 90% en poids de silice contenant un oxyde d'un métal divalent, p. ex. un oxyde de zinc
• C03C 3/097 - Compositions pour la fabrication du verre contenant de la silice avec 40 à 90% en poids de silice contenant du phosphore, du niobium ou du tantale

Abrégé

The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

Classes IPC  ?

• C07D 493/20 - Systèmes condensés en spiro
• A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention concerns novel specific iron-activable nitrogen-containing derivatives of salinomycin and narasin, their synthesis and their uses in therapy notably for the treatment of cancer. Also disclosed are pharmaceutically acceptable mediums and medicaments for preventing and/or treating cancer, and/or for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

Classes IPC  ?

• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a compound of the following formula (I) in which X is an anion, in which R1 and R2 are either together —CH3 or a C1-C4 alkyl such that, if R1 is a Cn+i alkyl, R2 is a Cn alkyl, and vice versa, n being an integer ranging from 1 to 3, i being an integer ranging from 1 to 3 and in which n+i ranges from 1 to 4; and in which R3 is a —CH3 or a C2-C8 alkyl, said C2-C8 alkyl being optionally substituted with one or more heteroatoms.

Classes IPC  ?

• C07D 241/46 - Phénazines
• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent

Abrégé

The invention concerns a device (10) comprising: — a barrel (12); — an elastic system (14) separating the barrel into a solution chamber (36) and a depressurized chamber (38); — a first opening (16) to the solution chamber; — a piston (18) able to be moved inside the depressurized chamber from a rest configuration to a pulled configuration in order to suck said solution into the solution chamber; — a second opening (20) communicating with the depressurized chamber via a flow restrictor (21), and — a regulation system (22) able to close the second opening to make the depressurized chamber airtight when the piston is sucking the solution and able to open the second opening to release the elastic system and to eject the solution out of the solution chamber.

Classes IPC  ?

• A61M 5/31 - Seringues Parties constitutives
• A61M 5/19 - Seringues avec plusieurs compartiments
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage

Abrégé

Methods and systems for performing a bioproduction process are described, the bioproduction process comprising the production of a cellular product by a cell population. The methods include the steps of culturing the cell population at least partially embedded in a hydrogel matrix forming a three-dimensional structure.

Classes IPC  ?

• C12P 21/00 - Préparation de peptides ou de protéines
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

A method for fluorescence microscopic imaging of an object may be performed by means of a fluorescence microscopic imaging system with light sheet illumination. The method includes generating a line of light and scanning the line of light to generate a light sheet and further includes performing a wavefront analysis on an analysis field of the object. The method further includes applying spatial filtering of the fluorescence light, where the spatial filtering includes scanning a filtering element with respect to a fluorescence image of the line of light formed in a filtering plane of the filtering element. The scanning of the filtering element may be synchronized with the scanning of the line of light such as to obtain a superposition, at each instant, of the filtering element and the fluorescence image of the line of light.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence